OCILY19 cells were treated with 48nM gemcitabine for 1h and 8h (with 8h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.